메뉴 건너뛰기




Volumn 372, Issue 25, 2015, Pages 2387-2397

Ezetimibe added to statin therapy after acute coronary syndromes

(2,504)  Cannon, Christopher P a   Blazing, Michael A b   Giugliano, Robert P a   McCagg, Amy a   White, Jennifer A b   Theroux, Pierre c   Darius, Harald d   Lewis, Basil S e   Ophuis, Ton Oude f   Jukema, J Wouter g   De Ferrari, Gaetano M h   Ruzyllo, Witold i   De Lucca, Paul j   Im, KyungAh a   Bohula, Erin A a   Reist, Craig b   Wiviott, Stephen D a   Tershakovec, Andrew M j   Musliner, Thomas A j   Braunwald, Eugene a   more..


Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; THIENOPYRIDINE DERIVATIVE; AZETIDINE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; TRIACYLGLYCEROL;

EID: 84931411520     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1410489     Document Type: Article
Times cited : (3486)

References (41)
  • 1
    • 0027987849 scopus 로고
    • Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
    • Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
    • (1994) Lancet , vol.344 , pp. 1383-1389
  • 2
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
    • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
    • (2002) Lancet , vol.360 , pp. 7-22
  • 3
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3
  • 4
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials
    • Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
    • (2010) Lancet , vol.376 , pp. 1670-1681
    • Baigent, C.1    Blackwell, L.2    Emberson, J.3
  • 5
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 6
    • 4544243333 scopus 로고    scopus 로고
    • Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial
    • de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307-16.
    • (2004) JAMA , vol.292 , pp. 1307-1316
    • De Lemos, J.A.1    Blazing, M.A.2    Wiviott, S.D.3
  • 7
    • 15944410609 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
    • (2005) N Engl J Med , vol.352 , pp. 1425-1435
    • LaRosa, J.C.1    Grundy, S.M.2    Waters, D.D.3
  • 8
    • 27744603499 scopus 로고    scopus 로고
    • High-dose atorvastatin vs usualdose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial
    • Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usualdose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45.
    • (2005) JAMA , vol.294 , pp. 2437-2445
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.3
  • 9
    • 33746355566 scopus 로고    scopus 로고
    • Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
    • Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48:438-45.
    • (2006) J Am Coll Cardiol , vol.48 , pp. 438-445
    • Cannon, C.P.1    Steinberg, B.A.2    Murphy, S.A.3    Mega, J.L.4    Braunwald, E.5
  • 10
    • 79959428660 scopus 로고    scopus 로고
    • Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: A meta-analysis
    • Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensivedose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64.
    • (2011) JAMA , vol.305 , pp. 2556-2564
    • Preiss, D.1    Seshasai, S.R.2    Welsh, P.3
  • 11
    • 77951704587 scopus 로고    scopus 로고
    • Effects of combination lipid therapy in type 2 diabetes mellitus
    • Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
    • (2010) N Engl J Med , vol.362 , pp. 1563-1574
    • Ginsberg, H.N.1    Elam, M.B.2    Lovato, L.C.3
  • 12
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
    • (2011) N Engl J Med , vol.365 , pp. 2255-2267
    • Boden, W.E.1    Probstfield, J.L.2    Anderson, T.3
  • 13
    • 84904252744 scopus 로고    scopus 로고
    • Effects of extended-release niacin with laropiprant in high-risk patients
    • Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.
    • (2014) N Engl J Med , vol.371 , pp. 203-212
    • Landray, M.J.1    Haynes, R.2    Hopewell, J.C.3
  • 14
    • 84870045994 scopus 로고    scopus 로고
    • Effects of dalcetrapib in patients with a recent acute coronary syndrome
    • Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.
    • (2012) N Engl J Med , vol.367 , pp. 2089-2099
    • Schwartz, G.G.1    Olsson, A.G.2    Abt, M.3
  • 15
    • 0037044454 scopus 로고    scopus 로고
    • Inhibition of intestinal cholesterol absorption by ezetimibe in humans
    • Sudhop T, Lütjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943-8.
    • (2002) Circulation , vol.106 , pp. 1943-1948
    • Sudhop, T.1    Lütjohann, D.2    Kodal, A.3
  • 16
    • 18544390238 scopus 로고    scopus 로고
    • Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
    • Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309-19.
    • (2002) Br J Clin Pharmacol , vol.54 , pp. 309-319
    • Kosoglou, T.1    Meyer, I.2    Veltri, E.P.3
  • 17
    • 2942607406 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia
    • Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94.
    • (2004) Am J Cardiol , vol.93 , pp. 1487-1494
    • Ballantyne, C.M.1    Blazing, M.A.2    King, T.R.3    Brady, W.E.4    Palmisano, J.5
  • 18
    • 84864753387 scopus 로고    scopus 로고
    • Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials
    • Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012;223:251-61.
    • (2012) Atherosclerosis , vol.223 , pp. 251-261
    • Morrone, D.1    Weintraub, W.S.2    Toth, P.P.3
  • 19
    • 84915819121 scopus 로고    scopus 로고
    • Inactivating mutations in NPC1L1 and protection from coronary heart disease
    • Stitziel NO, Won HH, Morrison AC, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014;371:2072-82.
    • (2014) N Engl J Med , vol.371 , pp. 2072-2082
    • Stitziel, N.O.1    Won, H.H.2    Morrison, A.C.3
  • 20
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
    • Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
    • (2004) Circulation , vol.110 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.B.3
  • 21
    • 84862119222 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
    • Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.
    • (2012) Eur Heart J , vol.33 , pp. 1635-1701
    • Perk, J.1    De Backer, G.2    Gohlke, H.3
  • 22
    • 50949102416 scopus 로고    scopus 로고
    • Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes
    • Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-32.
    • (2008) Am Heart J , vol.156 , pp. 826-832
    • Cannon, C.P.1    Giugliano, R.P.2    Blazing, M.A.3
  • 23
    • 84905040766 scopus 로고    scopus 로고
    • Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: Final baseline characteristics of the IMPROVE-IT study population
    • Blazing MA, Giugliano RP, Cannon CP, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014;168(2):205.e1-212.e1.
    • (2014) Am Heart J , vol.168 , Issue.2 , pp. 205e1-212e1
    • Blazing, M.A.1    Giugliano, R.P.2    Cannon, C.P.3
  • 24
    • 77951622890 scopus 로고    scopus 로고
    • An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design
    • Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 2010;159:705-9.
    • (2010) Am Heart J , vol.159 , pp. 705-709
    • Califf, R.M.1    Lokhnygina, Y.2    Cannon, C.P.3
  • 25
    • 66149124479 scopus 로고    scopus 로고
    • Early versus delayed, provisional eptifibatide in acute coronary syndromes
    • Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009;360:2176-90.
    • (2009) N Engl J Med , vol.360 , pp. 2176-2190
    • Giugliano, R.P.1    White, J.A.2    Bode, C.3
  • 26
    • 33645762226 scopus 로고
    • A sharper Bonferroni procedure for multiple tests of significance
    • Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
    • (1988) Biometrika , vol.75 , pp. 800-802
    • Hochberg, Y.1
  • 27
    • 0034526070 scopus 로고    scopus 로고
    • Results of the lowdose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: Do stopped trials contribute to overall knowledge?
    • GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico). Results of the lowdose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 2000;1:810-20.
    • (2000) Ital Heart J , vol.1 , pp. 810-820
  • 28
    • 0037132607 scopus 로고    scopus 로고
    • Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
    • ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
    • (2002) JAMA , vol.288 , pp. 2998-3007
  • 29
    • 10744229858 scopus 로고    scopus 로고
    • Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial
    • Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-31.
    • (2003) Lancet , vol.361 , pp. 2024-2031
    • Holdaas, H.1    Fellström, B.2    Jardine, A.G.3
  • 30
    • 0037178569 scopus 로고    scopus 로고
    • Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial
    • Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22.
    • (2002) JAMA , vol.287 , pp. 3215-3222
    • Serruys, P.W.1    De Feyter, P.2    Macaya, C.3
  • 31
    • 0032572086 scopus 로고    scopus 로고
    • Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
    • Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
    • (1998) JAMA , vol.279 , pp. 1615-1622
    • Downs, J.R.1    Clearfield, M.2    Weis, S.3
  • 32
    • 0342981862 scopus 로고    scopus 로고
    • The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators
    • Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
    • (1996) N Engl J Med , vol.335 , pp. 1001-1009
    • Sacks, F.M.1    Pfeffer, M.A.2    Moye, L.A.3
  • 33
    • 0032487931 scopus 로고    scopus 로고
    • Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
    • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
    • (1998) N Engl J Med , vol.339 , pp. 1349-1357
  • 34
    • 0037164314 scopus 로고    scopus 로고
    • PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial
    • Shepherd J, Blauw GJ, Murphy MB, et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
    • (2002) Lancet , vol.360 , pp. 1623-1630
    • Shepherd, J.1    Blauw, G.J.2    Murphy, M.B.3
  • 35
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
    • Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.
    • (2003) Lancet , vol.361 , pp. 1149-1158
    • Sever, P.S.1    Dahlöf, B.2    Poulter, N.R.3
  • 36
    • 0028883828 scopus 로고
    • Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
    • Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
    • (1995) N Engl J Med , vol.333 , pp. 1301-1307
    • Shepherd, J.1    Cobbe, S.M.2    Ford, I.3
  • 37
    • 0031030620 scopus 로고    scopus 로고
    • The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
    • Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
    • (1997) N Engl J Med , vol.336 , pp. 153-162
  • 38
    • 4344683381 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial
    • Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
    • (2004) Lancet , vol.364 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durrington, P.N.3
  • 39
    • 58149223233 scopus 로고    scopus 로고
    • Preliminary observations from preliminary trial results: Have we finally had enough?
    • Taylor AJ, Nissen SE. Preliminary observations from preliminary trial results: have we finally had enough? Circ Cardiovasc Qual Outcomes 2008;1:54-7.
    • (2008) Circ Cardiovasc Qual Outcomes , vol.1 , pp. 54-57
    • Taylor, A.J.1    Nissen, S.E.2
  • 40
    • 68849108178 scopus 로고    scopus 로고
    • Premature release of data from clinical trials of ezetimibe
    • Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med 2009;361:712-7.
    • (2009) N Engl J Med , vol.361 , pp. 712-717
    • Califf, R.M.1    Harrington, R.A.2    Blazing, M.A.3
  • 41
    • 84906675153 scopus 로고    scopus 로고
    • Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention
    • Laufs U, Descamps OS, Catapano AL, Packard CJ. Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention. Eur Heart J 2014;35:1996-2000.
    • (2014) Eur Heart J , vol.35 , pp. 1996-2000
    • Laufs, U.1    Descamps, O.S.2    Catapano, A.L.3    Packard, C.J.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.